Liver Cancer

Stivarga (regorafenib) proved to have better overall survival for patients with HCC in a recent phase 3 trial.

Nurses and oncologists need to give portal vein thrombosis a closer look, according to one oncolgy nurse.

A number of novel therapies are currently being explored as second-line treatments for patients with advanced hepatocellular carcinoma (HCC), including a host of targeted therapies and various immune checkpoint inhibitors.

There are currently 30 million Americans with some form of liver disease. Through education and advocacy, the American Liver Foundation wants to decrease that number.

In this segment, David Liu, shares a case study of a 33-year-old woman with stage 4 colorectal cancer that had metastasized to the liver.